Systemic treatments for high-risk localized prostate cancer

Area of Science:

• Oncology
• Urology

Background:

• High-risk localized prostate cancer often progresses to lethal metastatic disease.
• Effective treatment strategies at the localized stage are critical for improving patient outcomes.

Purpose of the Study:

• To review the potential of multimodal treatment approaches for high-risk localized prostate cancer.
• To explore the role of systemic therapies, including chemotherapy and hormonal agents, in combination with local treatments.

Main Methods:

• Review of current treatment standards and emerging therapeutic strategies for prostate cancer.
• Analysis of the evidence for multimodal therapies in localized and advanced prostate cancer settings.

Main Results:

• Androgen deprivation therapy combined with radiotherapy is a standard for high-risk localized/locally advanced prostate cancer.
• The benefit of chemotherapy or chemohormonal therapy in the non-metastatic setting remains to be demonstrated.
• The efficacy of neoadjuvant/adjuvant systemic therapies with radical prostatectomy is not yet proven.

Conclusions:

• Multimodal treatment combining systemic and local therapies holds promise for high-risk localized prostate cancer.
• Further investigation into chemotherapy, chemohormonal therapy, and next-generation hormonal agents is warranted.
• Clinical trials are assessing novel therapeutic possibilities for prostate cancer management.